We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hepatic Tumor Growth: Target for Angiogenesis Inhibition?
- Authors
Sarraf-Yazdi, Shiva; Jing Mi; Clary, Bryan M.
- Abstract
Pathologic angiogenesis induced by a tumor is essential for its survival. The promise of tumor inhibition by targeting angiogenesis over the past several years has translated into numerous ongoing clinical trials. Recently, in a phase ill trial involving patients with metastatic colorectal cancer. Bevacizumab (Genentech, Inc, San Francisco, CA), a recombinant humanized monoclonal antibody against vascular endothelial growth factor used in conjunction with standard chemotherapy was shown to increase survival, progression-free survival, response rate, and duration of response compared to chemotherapy alone. Thus far, duration of the increased response remains less than 6 months. The majority of deaths in patients with colorectal cancer are related to hepatic metastases, it is hoped that novel approaches directed at the complex interactions between tumor and microenvironment in the angiogenic process will strengthen the therapeutic armamentarium against hepatic malignancies.
- Subjects
TUMOR growth; NEOVASCULARIZATION; COLON cancer; CANCER patients; METASTASIS; VASCULAR endothelial growth factors; MONOCLONAL antibodies
- Publication
World Journal of Surgery, 2005, Vol 29, Issue 3, p287
- ISSN
0364-2313
- Publication type
Article
- DOI
10.1007/s00268-004-7810-9